Caribou Biosciences (CRBU) Citi’s 19th Annual BioPharma Conference 2024 summary

Key approaches and differentiation in allogeneic cell therapy

• Strategies focus on overcoming both innate and adaptive immune rejection to enable allogeneic transplants without immune recognition.

• Gene editing (e.g., MHC class I/II knockout, CD47 overexpression) and iPSC-derived cell platforms are central to product differentiation.

• Off-the-shelf CAR T and NK cell therapies are being developed for both oncology and autoimmune indications, with scalability and cost-effectiveness as priorities.

• Unique gene edits (e.g., PD-1 knockout, TRAC locus insertion) aim to enhance persistence, reduce exhaustion, and eliminate GVHD risk.

• Allogeneic products are positioned as more accessible and less burdensome than autologous therapies, especially for autoimmune patients.

Clinical development highlights and data updates

• Multiple phase I studies are ongoing for off-the-shelf CAR T therapies in hematologic malignancies and autoimmune diseases.

• HLA matching (minimum four alleles) in CAR T therapy correlates with improved outcomes and is being incorporated into new trial cohorts.

• Upcoming data readouts are expected in the next two to three quarters for key programs in autoimmune disease, lymphoma, myeloma, and solid tumors.

• In vivo CAR T programs are advancing, with preclinical studies showing promising delivery and safety; human trials are not expected before 2026.

• Type 1 diabetes program is progressing, with gene-modified islet cell transplants aiming to demonstrate immune evasion and functional cure potential.

Industry trends and future outlook

• Cell-based therapies are seen as potentially curative for autoimmune diseases, offering a shift from chronic management to immune reset.

• Off-the-shelf, scalable, and cost-effective products are expected to broaden patient access, including in community settings.

• Multiplex gene editing and immune cloaking strategies are being explored to enhance efficacy and overcome tumor microenvironment challenges.

• Partnerships and capital needs are influencing development timelines and data disclosure strategies.

• The field anticipates multiple modalities and targets will be needed to address the heterogeneity of autoimmune syndromes.